EVALUATION OF THE POTENTIAL CYTOTOXICITY OF RUTHENIUM COMPLEX II AGAINST U-373 GLIOBLASTOMA CELLS
DOI:
https://doi.org/10.22159/ijap.2023v15i6.48940Keywords:
Anticancer agents, Coordination complexes, Cytotoxic activity, Ruthenium, Tumor cell linesAbstract
Objective: The potential of ruthenium complexes as anticancer agents has gained significant attention in the scientific community. The aim of this study was to investigate the effect of dithiocyanato-N-bis[8(diphenylphosphino)quinoline]ruthenium (II), [Ru(N-P)2(NCS)2] on the glioblastoma U-373 tumor cells and apoptosis.
Methods: Ru(N-P)2(NCS)2] was synthesized and characterized using FTIR, and X-ray crystallography. The cytotoxic effects of [Ru(N-P)2(NCS)2] on glioblastoma U-373 tumor cells were evaluated using both the trypan blue assay and the activity of caspase-3 to detect apoptosis. A DPPH scavenging assay was used to evaluate the antioxidant activity.
Results: The [Ru(N-P)2(NCS)2] complex effectively inhibited the glioblastoma U-373 tumor cells with an IC50 of ~ 23 µg/ml. Similar to the majority of chemotherapeutic agents that kill via the intrinsic pathway, [Ru(N-P)2(NCS)2] induces apoptosis, which was confirmed by the activation of caspase-3, and these effects were dose-dependent. Ruthenium has antioxidant properties, so ruthenium Complex II exhibits lower toxicity towards normal cells while effectively targeting and eliminating cancer cells.
Conclusion: [Ru(N-P)2(NCS)2] is considered promising for researchers investigating putative biological activities, particularly antitumor and immune-related activity.
Downloads
References
Zuba I, Zuba M, Piotrowski M, Pawlukojc A. Ruthenium as an important element in nuclear energy and cancer treatment. Appl Radiat Isot. 2020;162:109176. doi: 10.1016/j.apradiso.2020.109176, PMID 32310093.
Dabiri Y, Schmid A, Theobald J, Blagojevic B, Streciwilk W, Ott I. A ruthenium (II) N-heterocyclic carbene (NHC) complex with naphthalimide ligand triggers apoptosis in colorectal cancer cells via activating the ROS-p38 MAPK pathway. Int J Mol Sci. 2018;19(12):3964. doi: 10.3390/ijms19123964, PMID 30544880.
Lam NYS, Truong D, Burmeister H, Babak MV, Holtkamp HU, Movassaghi S. From catalysis to cancer: toward structure-activity relationships for benzimidazol-2-ylidene-derived n-heterocyclic-carbene complexes as anticancer agents. Inorg Chem. 2018;57(22):14427-34. doi: 10.1021/acs.inorgchem.8b02634. PMID 30406647.
Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889-901. doi: 10.1517/14656566.4.6.889, PMID 12783586.
Li Y, Liu B, Shi H, Wang Y, Sun Q, Zhang Q. Metal complexes against breast cancer stem cells. Dalton Trans. 2021;50(41):14498-512. doi: 10.1039/D1DT02909F, PMID 34591055.
Kanaoujiya R, Meenakshi, Srivastava S, Singh R, Mustafa G. Recent advances and application of ruthenium complexes in tumor malignancy. Mater Today Proc. 2023;72:2822-7. doi: 10.1016/j.matpr.2022.07.098.
Al-Wahish MA, Awwadi FF, Al-Shwieki RK, Hodali HA. Ruthenium(II) complexes with 8-(diphenylphosphino)quinoline: synthesis, spectroscopic properties, and single-crystal X-ray structures. Inorg Nano Met Chem. 2017;47(5):655-60. doi: 10.1080/15533174.2016.1212225.
Awwadi FF, Hodali HA, Hodali HA. Synthesis, spectroscopic properties and single crystal x-ray structure of dithiocyanato-N-bis[8-(diphenylphosphino)-quinoline]ruthenium(II). Jordan J Chem. 2022;17(2):85-9. doi: 10.47014/17.2.3.
Abusamra YA, Scuruchi M, Habibatni S, Maammeri Z, Benayache S, D’Ascola A. Evaluation of putative cytotoxic activity of crude extracts from onopordum acanthium leaves and spartium junceum flowers against the U-373 glioblastoma cell line. Pak J Pharm Sci. 2015;28(4):1225-32. PMID 26142501.
Bajes HR, Oran SA, Bustanji YK. Chemical composition and antiproliferative and antioxidant activities of methanolic extract of Alcea setosa A. Malvaceae. Res J Pharm Technol. 2021;14(12):6447-54. doi: 10.52711/0974-360X.2021.01115.
Hu H, Zhang H, Zhong R, Yang Y, Huang C, Chen J. Synthesis, RNA-sequence and evaluation of anticancer efficacy of ruthenium(II) polypyridyl complexes toward HepG2 cells. J Inorg Biochem. 2023;244:112230. doi: 10.1016/j.jinorgbio.2023.112230, PMID 37084581.
Bhamare VS, Kulkarni RM. Photocatalytic degradation of pharmaceutical drug zidovudine by undoped and 5 % barium doped zinc oxide nanoparticles during water treatment: synthesis and characterisation. Int J App Pharm. 2019;11(1):227-36. doi: 10.22159/ijap.2019v11i1.30350.
Sahu VK, Sharma N, Sahu PK, Saraf SA. Formulation and evaluation of floating-mucoadhesive microspheres of novel natural polysaccharide for site-specific delivery of ranitidine hydrochloride. Int J App Pharm. 2017;9(3):15-9. doi: 10.22159/ijap.2017v9i3.16137.
Kostova I. Ruthenium complexes as anticancer agents. Curr Med Chem. 2006;13(9):1085-107. doi: 10.2174/092986706776360941, PMID 16611086.
Kanaoujiya R, Meenakshi, Srivastava S, Singh R, Mustafa G. Recent advances and application of ruthenium complexes in tumor malignancy. Mater Today Proc. 2023;72:2822-7. doi: 10.1016/j.matpr.2022.07.098.
Wilke NL, Burmeister H, Frias C, Ott I, Prokop A. Ruthenium complex HB324 induces apoptosis via a mitochondrial pathway with an upregulation of Harakiri and overcomes cisplatin resistance in neuroblastoma cells in vitro. Int J Mol Sci. 2023;24(2):952. doi: 10.3390/ijms24020952, PMID 36674465.
Huang C, Zhang H, Yang Y, Liu H, Chen J, Wang Y. Synthesis, characterization, molecular docking, RNA-sequence and anticancer efficacy evaluation in vitro of ruthenium(II) complexes on B16 cells. J Inorg Biochem. 2023;247:112329. doi: 10.1016/j.jinorgbio.2023.112329, PMID 37478780.
Zhang SQ, Meng TT, Li J, Hong F, Liu J, Wang Y. Near-IR/visible-emitting thiophenyl-based Ru(II) complexes: efficient photodynamic therapy, cellular uptake, and DNA binding. Inorg Chem. 2019;58(20):14244-59. doi: 10.1021/acs.inorgchem.9b02420, PMID 31595752.
Chen BC, Lu JJ, Jiang N, Ma XR, Li RT, Ye RR. Synthesis, characterization and antitumor mechanism investigation of ruthenium (II) polypyridyl complexes with artesunate moiety. J Biol Inorg Chem. 2021;26(8):909-18. doi: 10.1007/s00775-021-01901-8, PMID 34545414.
Anitha P, Bhargavi J, Sravani G, Aruna B, Ramkanth S. Recent progress of dendrimers in drug delivery for cancer therapy. Int J App Pharm. 2018;10(5):34-42, doi: 10.22159/ijap.2018v10i5.27075.
Balakrishnan SK, Dass SK, Rajendran HA, Savrimuthu I. Cytotoxicity and antimicrobial activity of mono-, di-and trinuclear ruthenium (II) Polypyridine complexes. Int J Pharm Pharm Sci. 2015;7:317-21.
Kahrovic E, Pavelic SK. Antiproliferative effect and selectivity of sodium dichloro-bis [n-phenyl-5-chloro-salicylideneiminato-n, O] ruthenate (III) in vitro. Int J Pharm Pharm Sci. 2015;7:86-8.
Published
How to Cite
Issue
Section
Copyright (c) 2023 MOHAMED J. SAADH
This work is licensed under a Creative Commons Attribution 4.0 International License.
